Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax Inc (NASDAQ: NVAX) announced preclinical and clinical data on its recombinant protein COVID-19 vaccine candidate, NVX-CoV2373, directed against the SARS-CoV-2 Beta (B.1.351) variant identified in South Africa. The vaccine candidate is advancing in two Phase 2 studies, including a Phase 2b trial in South Africa.

Novavax's COVID-19 Vaccine Candidate Showed Immune Response, Protection Against Variants

Novavax: Late-stage study finds vaccine 90% effective against coronavirus

The biotech company Novavax said on Monday that its coronavirus vaccine succeeded in a final-stage clinical trial, demonstrating 90% efficacy at preventing COVID-19.  Novavax had previously announced results from smaller studies in the UK and South Africa that suggested that its two-dose vaccine works. Data from the larger study will allow Novavax to submit the shot to US regulators. The company plans to file by the end of September.

Novavax says its coronavirus vaccine was 90% effective in a large trial, moving the shot a step closer to widespread use

If Novavax's vaccine is authorized, it would follow three Covid shots already approved for emergency use in the U.S. from Pfizer-BioNTech, Moderna and J&J.

Novavax says its Covid vaccine is 90% effective, plans to submit data to FDA in third quarter

93% efficacy against predominantly circulating Variants of Concern and Variants of Interest 91% efficacy in high-risk populations 100% efficacy against variants "not considered Variants of Concern/Interest" All COVID-19 hospitalizations/death occurred in the placebo group Company to host investor conference call today at 8:30 am ET GAITHERSBURG, Md., June 14, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), today announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% protection against moderate and severe disease, 90.4% efficacy overall, and met the primary endpoint in its PREVENT-19 pivotal Phase 3 trial.

Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial

Novavax has said its COVID-19 vaccine is 100% effective in protecting against "moderate and severe disease" following its phase three trial results.

Novavax COVID jab 100% effective in protecting against moderate and severe disease, trial suggests

Ocugen, Inc.

Which Stocks Are the Biggest Losers From the FDA's COVID Vaccine Authorization Changes?

GAITHERSBURG, Md., June 11, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced preclinical and clinical data on the company's recombinant protein COVID-19 vaccine candidate, NVX-CoV2373, directed against the SARS-CoV-2 Beta (B.1.351) variant, which was originally identified in South Africa.

Novavax Announces Positive Data from Three Complementary Studies of COVID-19 Beta (B.1.351) Variant Strain Vaccine

While vaccines and diagnostics have been the big winners in the space so far, Humanigen might make investors a lot of money with its drug to treat cytokine storms caused by COVID-19.

Why This COVID-19 Stock Is On Fire Right Now

Why Shares of Novavax Crashed 37.7% in May

First Majestic Silver

Vertex Pharmaceuticals

Unlike the "people's currency," these companies offer tangible growth that can make investors rich.

Ditch Dogecoin: These Stocks Are Screaming Buys in June

Novavax (NVAX) reported earnings 30 days ago. What's next for the stock?

Why Is Novavax (NVAX) Up 43.9% Since Last Earnings Report?

GAITHERSBURG, Md., June 9, 2021 /PRNewswire/ -- Novavax, Inc. (NASDAQ: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, will host Maryland Governor Larry Hogan at the site of the company's planned Vaccines Innovation Campus and global headquarters in Gaithersburg on Thursday, June 10 at 9:30 AM ET.

Novavax to Host Maryland Governor Larry Hogan at Site of Future Novavax Vaccines Innovation Campus and Global Headquarters

NVAX stock will release trial data soon and has multiple ways to win making it worth a look right now. The post There's Good Reason to Believe Novavax Will Rise Soon appeared first on InvestorPlace.

There's Good Reason to Believe Novavax Will Rise Soon

Let's look to where the company might generate sales.

Should You Worry About Novavax's Vaccine Delay?

GAITHERSBURG, Md., June 7, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Stanley C.

Novavax to Participate in Panel at BIO Digital 2021

Inovio Pharmaceuticals

Moderna

Pfizer

Vaxart

These Vaccine Latecomers Could Still Win Big. Here's How

Here's What to Expect from Vaccine Makers in the Long Term

Even as COVID-19 vaccines go unused in the U.S., there's plenty of worldwide opportunity for these two companies.

Thought These 2 Nasdaq Vaccine Stocks Were Done? Think Again

Stronger side effects and heart inflammation could potentially hamstring mRNA vaccines. Novavax has the winning proposition on a direct comparison with BioNTech and Moderna.

And The Booster Covid Vaccine Winner Is: Novavax

The company could have a bigger opportunity in the key Asian market.

What Investors Should Know About Novavax's South Korea Expansion

Could Novavax Have a Clinical Trial Mutiny on Its Hands?

NVAX management indicated again that it would soon unblind data for its Phase 3 clinical trial. NVAX is rising on the news. It could behoove the U.S. to have another vaccine as an alternative to PFE and MRNA.

Novavax To Provide Phase 3 Data Soon

Novavax stock has jumped 30% this week in anticipation of dramatically increasing production of its COVID-19 vaccine soon.

Novavax Stock Spikes as U.S. Releases Hold on Raw Materials for COVID-19 Vaccines

Novavax has seen its highs and lows, but its best days appear ahead of it. And for NVAX stock investors, the opportunity looks massive today!

News for Novavax Stock (NVAX)